A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice - COMPARE


The current trial sought to compare outcomes between the everolimus-eluting stent (EES) (Xience V) and paclitaxel-eluting stent (PES) (Taxus Liberte) in a real-world situation.

Contribution to the Literature: The COMPARE trial showed that EES is superior to PES at 5 years for MI, TVR, stent thrombosis, and MACE when used in a real-world setting.